On the public citation graph
Programmed death ligand‐1 expression is associated with poor disease free survival in salivary gland carcinomas
0 signed · 132 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19960115)77:2<223::aid-cncr1>3.0.co;2-nopenalex-snapshot
Salivary duct carcinoma: Clinicopathologic and immunohistochemical review of 26 cases
inferredcites →https://doi.org/10.1002/(sici)1097-0347(199703)19:2<126::aid-hed7>3.0.co;2-6openalex-snapshot
Salivary duct carcinoma: Clinical characteristics and treatment strategies
inferredcites →https://doi.org/10.1002/1097-0142(19810215)47:4<645::aid-cncr2820470404>3.0.co;2-aopenalex-snapshot
Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland
inferredcites →https://doi.org/10.1002/cncr.24899openalex-snapshot
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
inferredcites →https://doi.org/10.1007/s10549-014-2988-5openalex-snapshot
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
inferredcites →https://doi.org/10.1016/0030-4220(90)90271-sopenalex-snapshot
Undifferentiated carcinomas of the major salivary glands
inferredcites →https://doi.org/10.1016/j.acthis.2006.01.003openalex-snapshot
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
inferredcites →https://doi.org/10.1016/j.critrevonc.2009.10.004openalex-snapshot
Major and minor salivary gland tumors
inferredcites →https://doi.org/10.1016/j.ijrobp.2004.03.018openalex-snapshot
The role of radiotherapy in the treatment of malignant salivary gland tumors
inferredcites →https://doi.org/10.1016/s0360-3016(96)00464-6openalex-snapshot
Postoperative radiotherapy for malignant tumors of the parotid gland
inferredcites →https://doi.org/10.1034/j.1601-0825.2002.02870.xopenalex-snapshot
Salivary gland tumours
inferredcites →https://doi.org/10.1038/85330openalex-snapshot
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
inferredcites →https://doi.org/10.1038/labinvest.2013.130openalex-snapshot
Programmed death ligand-1 expression in non-small cell lung cancer
inferredcites →https://doi.org/10.1038/nm730openalex-snapshot
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-snapshot
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1200690openalex-snapshot
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
inferredcites →https://doi.org/10.1056/nejmoa1200694openalex-snapshot
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1056/nejmoa1305133openalex-snapshot
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
inferredcites →https://doi.org/10.1073/pnas.0406351101openalex-snapshot
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
inferredcites →https://doi.org/10.1073/pnas.192461099openalex-snapshot
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
inferredcites →https://doi.org/10.1080/02841860500543208openalex-snapshot
Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: An evaluation of 212 cases
inferredcites →https://doi.org/10.1084/jem.192.7.1027openalex-snapshot
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
inferredcites →https://doi.org/10.1093/annonc/mdu445openalex-snapshot
PD-L1 expression in nonclear-cell renal cell carcinoma
inferredcites →https://doi.org/10.1097/pat.0b013e3283484a60openalex-snapshot
Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas
inferredcites →https://doi.org/10.1126/scitranslmed.3003689openalex-snapshot
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-0428openalex-snapshot
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-2746openalex-snapshot
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
inferredcites →https://doi.org/10.1371/journal.pone.0131403openalex-snapshot
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
inferredcites →https://doi.org/10.1634/theoncologist.2012-0369openalex-snapshot
Trastuzumab for the Treatment of Salivary Duct Carcinoma
inferredcites →https://doi.org/10.32388/b30ldkopenalex-snapshot
AJCC Cancer Staging Manual 8th Edition
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4857103openalex-extracted
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer
inferred← citeshttps://doi.org/10.1002/cnr2.70125openalex-snapshot
Relationship Between Short‐Term Outcomes and PD ‐ L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐ PD ‐1 Antibody Monotherapy
inferred← citeshttps://doi.org/10.1002/hed.25468openalex-snapshot
Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease
inferred← citeshttps://doi.org/10.1002/hed.25857openalex-snapshot
Prognostic markers in salivary gland cancer and their impact on survival
inferred← citeshttps://doi.org/10.1002/hed.26529openalex-snapshot
Therapeutic implications of immune‐profiling and EGFR expression in salivary gland carcinoma
inferred← citeshttps://doi.org/10.1002/hed.27716openalex-snapshot
The tumor microenvironment of benign and malignant salivary gland tumors
inferred← citeshttps://doi.org/10.1002/lary.29120openalex-snapshot
Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma
inferred← citeshttps://doi.org/10.1007/978-3-030-02958-6_13openalex-snapshot
Systemic Therapy in Salivary Gland Carcinoma
inferred← citeshttps://doi.org/10.1007/978-3-319-98854-2_19openalex-snapshot
New Data on Systemic Therapy of Salivary Gland Tumors
inferred← citeshttps://doi.org/10.1007/978-3-662-62808-9_7openalex-snapshot
Karzinome der Speicheldrüsen
inferred← citeshttps://doi.org/10.1007/s00066-017-1196-8openalex-snapshot
Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma
inferred← citeshttps://doi.org/10.1007/s00262-020-02730-5openalex-snapshot
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
inferred← citeshttps://doi.org/10.1007/s10147-023-02416-9openalex-snapshot
Clinicopathological characteristics of four major histological types of high-grade parotid carcinoma
inferred← citeshttps://doi.org/10.1007/s12070-023-03906-yopenalex-snapshot
Pathogenesis Analysis of Salivary Gland Tumors Through the Expression of Programmed Death-Ligand 1 (PD-L1)
inferred← citeshttps://doi.org/10.1007/s12070-023-04104-6openalex-snapshot
Chemotherapy for Salivary Gland Malignant Carcinoma : Meta-analysis and Systemic Review
inferred← citeshttps://doi.org/10.1007/s12105-020-01163-xopenalex-snapshot
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression
inferred← citeshttps://doi.org/10.1007/s12105-021-01346-0openalex-snapshot
Myoepithelial Carcinoma Ex-Pleomorphic Adenoma: A Rare Pathology Misdiagnosed as Pleomorphic Adenoma; With a Novel TERT Promoter Mutation and High PD-L1 Expression
inferred← citeshttps://doi.org/10.1007/s12105-023-01528-yopenalex-snapshot
Prognostic Impact of Tumor Immune Microenvironment and Its Predictive Role in Salivary Gland Cancer
inferred← citeshttps://doi.org/10.1007/s12105-024-01629-2openalex-snapshot
Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland
inferred← citeshttps://doi.org/10.1007/s12105-024-01698-3openalex-snapshot
Pitfalls in Diagnosis of Myoepithelial Carcinoma of Salivary Glands: A Study of 3 Cases with Cytologic-histologic Correlation and Molecular Analysis
inferred← citeshttps://doi.org/10.1007/s12105-024-01726-2openalex-snapshot
Malignant Salivary Gland Neoplasm of the Tongue Base with EWSR1::BEND2 Fusion: An Unusual Case with Literature Review
inferred← citeshttps://doi.org/10.1007/s12672-022-00502-4openalex-snapshot
Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case
inferred← citeshttps://doi.org/10.1007/s40291-022-00576-4openalex-snapshot
Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1016/j.ajo.2020.07.031openalex-snapshot
High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.anndiagpath.2019.04.001openalex-snapshot
PD-L1 expression by immunohistochemistry in salivary duct carcinoma
inferred← citeshttps://doi.org/10.1016/j.annonc.2019.10.024openalex-snapshot
Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma
inferred← citeshttps://doi.org/10.1016/j.annpat.2016.12.013openalex-snapshot
Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures
inferred← citeshttps://doi.org/10.1016/j.archoralbio.2017.07.004openalex-snapshot
Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma
inferred← citeshttps://doi.org/10.1016/j.clicom.2022.09.004openalex-snapshot
Her2 expression can predict the survival of patients with salivary duct carcinoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103605openalex-snapshot
Salivary gland cancer in the setting of tumor microenvironment: Translational routes for therapy
inferred← citeshttps://doi.org/10.1016/j.ctrv.2024.102697openalex-snapshot
Salivary gland carcinoma: Towards a more personalised approach
inferred← citeshttps://doi.org/10.1016/j.eclinm.2024.102991openalex-snapshot
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
inferred← citeshttps://doi.org/10.1016/j.ejso.2018.10.060openalex-snapshot
PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population
inferred← citeshttps://doi.org/10.1016/j.humpath.2018.07.024openalex-snapshot
Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2017.02.018openalex-snapshot
New concepts of personalized therapy in salivary gland carcinomas
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2017.09.008openalex-snapshot
Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2018.11.028openalex-snapshot
Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2019.01.015openalex-snapshot
Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2020.104931openalex-snapshot
Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2022.105777openalex-snapshot
Tumor microenvironment in salivary gland carcinomas: An orchestrated state of chaos
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2022.105905openalex-snapshot
Anti-PD-1 plus anti-HER2 and chemotherapy showed superior and durable clinical benefit in a patient with advanced salivary duct carcinoma
inferred← citeshttps://doi.org/10.1016/j.oraloncology.2022.105932openalex-snapshot
Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study
inferred← citeshttps://doi.org/10.1016/j.otc.2021.01.007openalex-snapshot
Molecular Markers that Matter in Salivary Malignancy
inferred← citeshttps://doi.org/10.1016/j.prp.2023.155005openalex-snapshot
Heterogeneity in PD-L1 expression in MAML2-rearranged mucoepidermoid carcinoma
inferred← citeshttps://doi.org/10.1038/s41591-023-02518-xopenalex-snapshot
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
inferred← citeshttps://doi.org/10.1038/s41598-019-49215-9openalex-snapshot
The expression of PD-L1 in salivary gland carcinomas
inferred← citeshttps://doi.org/10.1038/s41598-020-73965-6openalex-snapshot
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma
inferred← citeshttps://doi.org/10.1038/s41598-024-70779-8openalex-snapshot
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab
inferred← citeshttps://doi.org/10.1080/00016489.2019.1683604openalex-snapshot
Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma
inferred← citeshttps://doi.org/10.1080/0284186x.2020.1730005openalex-snapshot
Treatment outcomes of patients with salivary duct carcinoma undergoing surgery and postoperative radiotherapy
inferred← citeshttps://doi.org/10.1080/08830185.2021.1958806openalex-snapshot
Immunological and biological dissection of normal and tumoral salivary glands
inferred← citeshttps://doi.org/10.1080/13543784.2019.1598376openalex-snapshot
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?
inferred← citeshttps://doi.org/10.1080/14728222.2020.1804863openalex-snapshot
Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?
inferred← citeshttps://doi.org/10.1080/2162402x.2017.1288329openalex-snapshot
The immune molecular landscape of the B7 and TNFR immunoregulatory ligand–receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications
inferred← citeshttps://doi.org/10.1093/ejcts/ezy370openalex-snapshot
Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms
inferred← citeshttps://doi.org/10.1097/cco.0000000000000527openalex-snapshot
New approaches in salivary gland carcinoma
inferred← citeshttps://doi.org/10.1097/coc.0000000000000429openalex-snapshot
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma
inferred← citeshttps://doi.org/10.1097/iop.0000000000001585openalex-snapshot
PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications
inferred← citeshttps://doi.org/10.1097/pai.0000000000001209openalex-snapshot
PD-L1 and PD-L2 Expression in Different Tumor Stages and Types of Malignant Salivary Gland Neoplasms: A Single-center Experience
inferred← citeshttps://doi.org/10.1097/pap.0000000000000374openalex-snapshot
Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors in Head and Neck Cancer
inferred← citeshttps://doi.org/10.1101/mcs.a006189openalex-snapshot
Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report.
inferred← citeshttps://doi.org/10.1111/ajco.14108openalex-snapshot
Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer
inferred← citeshttps://doi.org/10.1111/his.13944openalex-snapshot
The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma
inferred← citeshttps://doi.org/10.1111/jop.12722openalex-snapshot
The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinoma
inferred← citeshttps://doi.org/10.1136/bmjonc-2023-000065openalex-snapshot
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)
inferred← citeshttps://doi.org/10.1136/jcp-2023-209059openalex-snapshot
PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study
inferred← citeshttps://doi.org/10.1155/2019/2305315openalex-snapshot
The Three P’s: Parotid, PD-L1, and Pembrolizumab
inferred← citeshttps://doi.org/10.1155/2022/9742091openalex-snapshot
Pulmonary Salivary Gland Tumor, Mucoepidermoid Carcinoma: A Literature Review
inferred← citeshttps://doi.org/10.1158/1055-9965.epi-18-0779openalex-snapshot
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1159/000512060openalex-snapshot
Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma
inferred← citeshttps://doi.org/10.1177/01455613251324353openalex-snapshot
The Role of Immunotherapy in Salivary Gland Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.1177/1724600818770941openalex-snapshot
Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis
inferred← citeshttps://doi.org/10.1177/17588359261451739openalex-snapshot
A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort
inferred← citeshttps://doi.org/10.1177/2036361320973526openalex-snapshot
Primary squamous cell carcinoma of major salivary gland: “Sapienza Head and Neck Unit” clinical recommendations
inferred← citeshttps://doi.org/10.1186/s41199-016-0011-zopenalex-snapshot
Systemic therapy for recurrent or metastatic salivary gland malignancies
inferred← citeshttps://doi.org/10.1200/jco.22.02328openalex-snapshot
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
inferred← citeshttps://doi.org/10.12677/acm.2026.1662458openalex-snapshot
Therapeutic Methods and Research Progress of Malignant Salivary Gland Tumors
inferred← citeshttps://doi.org/10.1371/journal.pone.0179536openalex-snapshot
Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1371/journal.pone.0272080openalex-snapshot
Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.17650/2222-1468-2020-10-3-65-71openalex-snapshot
Survival of patients with salivary gland malignancies depending on the molecular profile of the tumor
inferred← citeshttps://doi.org/10.18632/oncotarget.14174openalex-snapshot
Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.18632/oncotarget.24277openalex-snapshot
Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype
inferred← citeshttps://doi.org/10.21053/ceo.2019.00388openalex-snapshot
Evaluation of Prognostic Factors for the Parotid Cancer Treated With Surgery and Postoperative Radiotherapy
inferred← citeshttps://doi.org/10.21203/rs.2.12808/v1openalex-snapshot
Association between PD-L1 expression and head and neck cancer prognosis: a meta-analysis
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1433947/v1openalex-snapshot
Pembrolizumab as a first line therapy in a patient with extensive Mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1433947/v2openalex-snapshot
Pembrolizumab as a first line therapy in a patient with extensive Mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case
inferred← citeshttps://doi.org/10.21593/kjhno/2019.35.1.13openalex-snapshot
Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker
inferred← citeshttps://doi.org/10.3322/caac.21807openalex-snapshot
The evolving landscape of salivary gland tumors
inferred← citeshttps://doi.org/10.3389/fimmu.2022.988416openalex-snapshot
Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
inferred← citeshttps://doi.org/10.3389/fonc.2020.580141openalex-snapshot
Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease
inferred← citeshttps://doi.org/10.3389/fonc.2021.618201openalex-snapshot
Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
inferred← citeshttps://doi.org/10.3389/fonc.2021.701181openalex-snapshot
Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2022.1032471openalex-snapshot
Salivary gland cancers in elderly patients: challenges and therapeutic strategies
inferred← citeshttps://doi.org/10.3390/cancers12040873openalex-snapshot
Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
inferred← citeshttps://doi.org/10.3390/cancers13050965openalex-snapshot
Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands
inferred← citeshttps://doi.org/10.3390/cancers16061205openalex-snapshot
Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers
inferred← citeshttps://doi.org/10.3390/curroncol29090498openalex-snapshot
Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report
inferred← citeshttps://doi.org/10.3390/ijms232314891openalex-snapshot
The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?
inferred← citeshttps://doi.org/10.3390/jcm11030720openalex-snapshot
Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer
inferred← citeshttps://doi.org/10.47749/t/unicamp.2022.1253822openalex-snapshot
Diagnóstico e prognóstico do carcinoma mioepitelial de glândula salivar
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.